Comparative Pharmacology
Head-to-head clinical analysis: EXBLIFEP versus VIBATIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXBLIFEP versus VIBATIV.
EXBLIFEP vs VIBATIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exblifep is a beta-lactamase inhibitor combination consisting of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. Enmetazobactam inhibits Ambler class A and some class C beta-lactamases, restoring cefepime activity against beta-lactamase-producing Enterobacterales.
Lipoglycopeptide antibiotic that inhibits cell wall synthesis by binding to the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation and transpeptidation. Also disrupts membrane potential and increases membrane permeability.
2.5 g (cefepime 2 g, enmetazobactam 0.5 g) intravenously every 8 hours infused over 2 hours.
10 mg/kg intravenously once every 24 hours, infused over 60 minutes for 7 to 14 days.
None Documented
None Documented
The terminal elimination half-life of Exblifep is approximately 8-10 hours in patients with normal renal function. In patients with renal impairment, half-life is prolonged and dosing adjustments are required.
Terminal elimination half-life is approximately 177 hours (7.4 days), supporting once-daily dosing.
Exblifep is primarily excreted renally as unchanged drug (approximately 60-70% of the dose) and as the active metabolite nifepristone (approximately 20-30%). Fecal excretion accounts for <10% of the dose. Biliary excretion is minimal.
Primarily renal excretion as unchanged drug (approximately 93% of dose recovered in urine; <5% in feces).
Category C
Category C
Antibiotic
Antibiotic